StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
6557.T$632.00-2.32%
Fair $632.00+0.0%

6557.T

AIAI Group Corporation

Healthcare / Medical Care FacilitiesTokyo

$632.00

-15.00 (-2.32%)

Fairly Valued+0.0%Fair Value $632.00Fund rank 24/100 · Data gapFallback financials|
SA 30/D
F-Score: 8/9
High Debt

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 35% · confianza 12%

FCF escenarios

weak_data · normalized FCF $1.0B · quality 31.3/100

Data gap 24/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 28/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

30/100

D

Piotroski

8/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

16/100

SEC 0%

Latest source: unknownPeriods: 4Warnings: 1unknown: 4
No SEC-backed annual rows; valuation uses fallback financial data. Insufficient audited annual history (<3 SEC-backed years); composite fair value and forward targets are disabled until manually verified. Debt-to-Equity ratio is 2.54, above the 2.0 threshold
Thesis & Journal · 6557.TLocal privado en este navegador · AIAI Group Corporation
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$4.1B

P/E

6.8x

↓

EV/EBITDA

6.6x

↓

ROE

15.0%

↑

Gross Margin

16.4%

↓

Debt/Equity

2.54

↑
52-Week Range$632
$616$1622

TradingView lightweight chart

6557.T price, volumen y niveles de valoración

Último $632.00Periodo +144.0%
Fair value: $632.00

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2021–2025 · 4 años de histórico normalizado

Revenue CAGR

+8.5%

FCF CAGR

—

FCF margin

8.0%

FCF / Net income

2.46x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $13.07B · net income $421.9M · FCF $1.04B

2021-FY → 2025-FY

Gross margin

16.4%+5.3% pts

Operating margin

5.6%+10.3% pts

Net margin

3.2%+3.9% pts

FCF margin

8.0%+13.8% pts
MetricTTM
2025
2024
2023
2021
Income Statement
Revenue$13.07B$13.07B$11.82B$10.82B$9.43B
Net Income$421.9M$421.9M$353.3M$-506.1M$-65.2M
EBITDA$1.35B$1.35B$1.31B$651.2M$703.1M
EPS64.3664.3656.68-90.17-12.04
Gross Margin16.4%16.4%14.7%12.4%11.1%
Operating Margin5.6%5.6%4.5%0.7%-4.6%
Net Margin3.2%3.2%3.0%-4.7%-0.7%
Balance Sheet
Debt/Equity2.542.544.506.476.23
Current Ratio0.790.79———
Cash Flow
Free Cash Flow$1.04B$1.04B$1.19B$-15.1M$-555.6M
Returns
ROE15.0%15.0%20.2%-37.7%-4.6%
Valuation
P/E6.836.8312.06——
EV/EBITDA6.646.647.9714.7612.82
P/B1.471.472.441.671.37
Growth & Yield
Revenue Growth10.6%10.6%9.2%14.7%—
EPS Growth13.5%13.5%162.9%-649.2%—

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%

3Y implied EPS CAGR

-4.5%

fácil

EPS terminal req.

$56.08

Spread vs growth

18.0%

5Y implied EPS CAGR

1.1%

fácil

EPS terminal req.

$67.86

Spread vs growth

12.5%

10Y implied EPS CAGR

5.4%

razonable

EPS terminal req.

$109.28

Spread vs growth

8.1%

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · 1Y approxreconcilia total -51.4%

Total return

-51.4%

Start / end P/E

23.0x → 9.8x

EPS bridge

56.68 → 64.36

Residual

-7.8%

EPS growth+13.5%
Multiple rerating-57.2%
Dividend+0.0%
Residual / FX / buybacks / cross-term-7.8%

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.